Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in the ...

All other foot nails were dystrophic (Figure 1 ... dermal-epidermal junction detachment, suggestive of epidermolysis bullosa (EB) (Figure 2). A study of the pedigree of his family revealed ...

Recessive dystrophic epidermolysis bullosa is a rare, severely debilitating genetic disease ... CORDStrom was extremely well tolerated, with no serious adverse events related to CORDStrom reported at ...

Epidermolysis bullosa (EB) is the term given to a group ... There are three types of EB: simplex, junctional, and dystrophic. Each form has a specific cleavage plane within the epidermal-dermal ...

An international team led by researchers at the University of Toronto has found a compound in ginger, called furanodienone ...

Irritable bowel syndrome (IBS) is a combination of digestive ... such as gastrointestinal infections, cancer, IBD, celiac disease, bowel obstruction, and medication side effects.

A manikin created to look like it has Down's syndrome is being used to train hospital staff. Great Western Hospital, in Swindon, is using the child-sized manikin called Gwen to teach staff how to ...

Through use of precision medicine and machine learning (ML), the company’s cell-centred models will aid identification of patient subtypes and pair them with personalised IBD targets.

Oleogel-S10 is an effective and well-tolerated long-term treatment for epidermolysis bullosa, including patients with severe forms of the disease.